Elanco Animal Health Incorporated(ELAN)Earnings, Financials & Key Ratios

ELAN•NYSE

$24.64

Price updated Jul 7, 2026

SectorHealthcare IndustrySpecialty & Generic Pharma Sub-IndustryAnimal health pharmaceuticals and vaccines

AboutElanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.Show more

Revenue$4.71B+6.2%
EBITDA$932M+2.1%
Net Income-$232M-168.6%
EPS (Diluted)-0.47-169.1%
Gross Margin43.48%+1.1%
EBITDA Margin19.77%-3.9%
Operating Margin5.34%-5.5%
Net Margin-4.92%-164.6%
ROE-3.67%-166.9%

ELAN Price & Volume

Elanco Animal Health Incorporated (ELAN) stock price & volume — 10-year historical chart

Loading chart...

Volatile Margin Recovery Masks Persistent Debt Constraints

Investment Thesis • Updated 2026Q1

VerdictNeutral

Growth:Mixed

Profitability:Strained

Financial:Strained

Cash Flow:Mixed

Primary Risk:High debt leverage sensitivity

Key Thesis Takeaways

Elanco is currently navigating a complex transition characterized by aggressive deleveraging and a pivot toward operational efficiency, as evidenced by the reduction of total debt from $5.8 billion in 2023Q4 to $4.0 billion in 2026Q1.
While the company achieved a notable 14.9% revenue growth in 2026Q1, the underlying earnings quality remains obscured by significant non-cash charges and erratic profitability.
Investors should monitor whether the company can sustain its recent 22.4% operating margin while managing the $4.7 billion in goodwill that continues to dominate its asset base.

Verdict Logic

while the company has successfully reduced total debt to $4.0 billion, the persistent negative retained earnings of $2.1 billion and erratic free cash flow margins suggest that fundamental profitability remains unproven.

ELAN Growth Metrics

Elanco Animal Health Incorporated (ELAN) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years-

5 Years7.57%

3 Years2.25%

TTM10.53%

Profit CAGR

10 Years-

5 Years-

3 Years-

TTM-164.88%

EPS CAGR

10 Years-

5 Years-

3 Years-

TTM-165.58%

Return on Capital

10 Years2.47%

5 Years2.27%

3 Years2.22%

Last Year2.19%

ELAN Recent Earnings

Elanco Animal Health Incorporated (ELAN) EPS & revenue vs analyst estimates — last 4 quarters

Full history →

●Beat EPS 10/12 qtrs (83%)●Beat Revenue 11/12 qtrs (92%)

Q2 2026Latest

May 6, 2026

Metric

Actual

Est

EPS

$0.40+15.7%

$0.35

Rev

$1.4B+7.4%

$1.3B

Q1 2026

Feb 24, 2026

Metric

Actual

Est

EPS

$0.13+18.2%

$0.11

Rev

$1.1B+4.7%

$1.1B

Q4 2025

Nov 5, 2025

Metric

Actual

Est

EPS

$0.19+46.2%

$0.13

Rev

$1.1B+4.1%

$1.1B

Q3 2025

Aug 7, 2025

Metric

Actual

Est

EPS

$0.26+30.0%

$0.20

Rev

$1.2B+13.9%

$1.1B

Quarter	Date	EPS (Act vs Est)	Revenue (Act vs Est)
Q2 2026Latest	May 6, 2026	$0.40vs $0.35+15.7%	$1.4Bvs $1.3B+7.4%
Q1 2026	Feb 24, 2026	$0.13vs $0.11+18.2%	$1.1Bvs $1.1B+4.7%
Q4 2025	Nov 5, 2025	$0.19vs $0.13+46.2%	$1.1Bvs $1.1B+4.1%
Q3 2025	Aug 7, 2025	$0.26vs $0.20+30.0%	$1.2Bvs $1.1B+13.9%

Based on last 12 quarters of dataView full earnings history →

Latest ELAN News

Recent stock market news and headlines for Elanco Animal Health Incorporated (ELAN)

PRNewsWire·Jun 18, 2026

Elanco to Launch Elanco Ventures with $25 Million Multi-Year Commitment to Accelerate Innovation in Animal Health

New corporate venture capital platform will invest to advance therapeutics, technologies and One Health solutions INDIANAPOLIS, June 18, 2026 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today announced plans to establish Elanco Ventures, a dedicated corporate venture capital (CVC) platform designed to support, invest and advance innovation in animal health. To be backed by a $25 million multi-year commitment, Elanco Ventures will initially focus on strategic investments in therapeutic advancements and supportive technologies across the animal health sector.

Peers Comparison

Key metrics vs top competitors for Elanco Animal Health Incorporated (ELAN)

Full Screener →

Company	Price	Market Cap	P/E Ratio	Rev Growth (1Y)	Net Margin	ROE	Div Yield
ELANElanco Animal Health IncorporatedCurrent	$24.64	$12.31B	-52.43	6.22%	-4.92%	-3.67%	—
ZTSZoetis Inc.	$76.29	$31.98B	12.67	2.28%	27.79%	62.41%	—
PCRXPacira BioSciences, Inc.	$25.82	$1.02B	161.38	3.63%	1.27%	1.31%	—
PAHCPhibro Animal Health Corporation	$33.12	$1.34B	27.83	27.37%	6.35%	29.49%	—
NEOGNeogen Corporation	$9.39	$2.04B	-1.87	-3.2%	-69.93%	-29%	—
PETSPetMed Express, Inc.	$1.92	$41.02M	-0.70	-21.13%	-32%	-146.59%	—

Compare ELAN vs Peers

Elanco Animal Health Incorporated (ELAN) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs ZTS

Most directly comparable listed peer for ELAN.

Scale Benchmark

vs LLY

Larger-name benchmark to compare ELAN against a more recognizable public peer.

Peer Set

Compare Top 5

vs ZTS, PCRX, PAHC, NEOG

ELAN SEC Filings & Documents

Elanco Animal Health Incorporated (ELAN) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

Material company update

May 6, 2026·SEC

Material company update

Feb 24, 2026·SEC

Material company update

Jan 12, 2026·SEC

10-K Annual Reports

FY 2026

Feb 24, 2026·SEC

FY 2025

Feb 25, 2025·SEC

10-Q Quarterly Reports

FY 2026

May 6, 2026·SEC

FY 2025

Nov 5, 2025·SEC

FY 2025

Aug 7, 2025·SEC

Get notified when ELAN posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

ELAN Frequently Asked Questions

Elanco Animal Health Incorporated (ELAN) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials

What is Elanco Animal Health Incorporated's revenue?

Elanco Animal Health Incorporated (ELAN) reported $4.89B in revenue for fiscal year 2025. This represents a 68% increase from $2.91B in 2016.

How fast is Elanco Animal Health Incorporated growing?

Elanco Animal Health Incorporated (ELAN) grew revenue by 6.2% over the past year. This is steady growth.

Is ELAN profitable?

Elanco Animal Health Incorporated (ELAN) reported a net loss of $242.0M for fiscal year 2025.

Dividend & Returns

What is ELAN's return on equity?

Elanco Animal Health Incorporated (ELAN) has a return on equity (ROE) of -3.7%. Negative ROE indicates the company is unprofitable.

What is Elanco Animal Health Incorporated's free cash flow?

Elanco Animal Health Incorporated (ELAN) generated $315.0M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

What if you invested $1,000 in ELAN back in 2016?

Total return calculator · dividends reinvested · 10+ years of data

See returns →

Quarter

Date

EPS (Act vs Est)

Revenue (Act vs Est)

Q2 2026Latest

May 6, 2026

$0.40vs $0.35+15.7%

$1.4Bvs $1.3B+7.4%

Q1 2026

Feb 24, 2026

$0.13vs $0.11+18.2%

$1.1Bvs $1.1B+4.7%

Q4 2025

Nov 5, 2025

$0.19vs $0.13+46.2%

$1.1Bvs $1.1B+4.1%

Q3 2025

Aug 7, 2025

$0.26vs $0.20+30.0%

$1.2Bvs $1.1B+13.9%

Company

Price

Market Cap

P/E Ratio

Rev Growth (1Y)

Net Margin

ROE

Div Yield

ELANElanco Animal Health IncorporatedCurrent

$24.64

$12.31B

-52.43

6.22%

-4.92%

-3.67%

—

ZTSZoetis Inc.

$76.29

$31.98B

12.67

2.28%

27.79%

62.41%

—

PCRXPacira BioSciences, Inc.

$25.82

$1.02B

161.38

3.63%

1.27%

1.31%

—

PAHCPhibro Animal Health Corporation

$33.12

$1.34B

27.83

27.37%

6.35%

29.49%

—

NEOGNeogen Corporation

$9.39

$2.04B

-1.87

-3.2%

-69.93%

-29%

—

PETSPetMed Express, Inc.

$1.92

$41.02M

-0.70

-21.13%

-32%

-146.59%

—